智通财经APP讯，医思健康(02138)发布公告，集团预期截至2025年9月30日止6个月(报告期)的财务业绩 可能取得：(i)报告期内收入较截至2024年9月30日止相应期间约20.63亿港元相比，减少不多于10%;(ii) 报告期内于扣除利息、税项、拥有物业、厂房及设备的折旧及摊销前盈利(EBITDA)较截至2024年9月30 日止相应期间约2.48亿港元相比，减少不多于30%;及(iii)报告期除税后盈利(纯利)较截至2024年9月30日 止相应期间约4030万港元相比，减少不多于90%。 董事会认为，报告期内纯利和息税折旧及摊销前的盈利下降的主要原因是：(i)本地消费情绪疲弱，包括 香港居民于中国内地消费医疗及保健服务的趋势持续，以及外游增加，削弱了部分可自由支配医疗及医 美服务的本地需求;(ii)本集团于上一个财政年度下半年后期出售的若干医疗资产不再并入本集团财务报 表，因此于报告期内未能带来收入贡献;(iii)服务组合较不理想，高毛利的可自由支配服务占比下降;及 (iv)收入下降导致营运杠杆减弱。 董事会认为本集团的整体资产负债状况仍然稳健，于报告期末的现金、定期存款及流动金融资产合计预 期约为1 ...

(iii)报告期除税后盈利(「纯利」)较截至2024年9月30日止相应期间约港币4030万元相比，减少不多于 90%。董事会认为，报告期内纯利和息税折旧及摊销前之盈利下降的主要原因是： 格隆汇11月24日丨医思健康(02138.HK)经董事会基于目前可得之集团截至2025年9月30日止六个月(「报 告期」)初步未经审核综合管理账目进行最新评估后预期，集团于报告期之财务业绩可能录得： (i)报告期内收入较截至2024年9月30日止相应期间约港币20.63亿元相比，减少不多于10%； (ii)报告期内于扣除利息、税项、拥有物业、厂房及设备之折旧及摊销前盈利(「EBITDA」)较截至2024 年9月30日止相应期间约港币247.9百万元相比，减少不多于30%；及 (iii)服务组合较不理想，高毛利之可自由支配服务占比下降；及 (iv)收入下降导致营运杠杆减弱。 董事会认为集团之整体资产负债状况仍然稳健，于报告期末之现金、定期存款及流动金融资产合计预期 约为港币11亿元。 (i)本地消费情绪疲弱，包括香港居民于中国内地消费医疗及保健服务之趋势持续，以及外游增加，削弱 了部分可自由支配医疗及医美服务之本地需求； (ii ...

Core Viewpoint - The company, 港仔机器人, has issued a profit warning indicating an expected increase in net losses for the upcoming interim period, primarily due to share-based payment expenses and losses from the sale of subsidiaries [1]. Financial Performance - The company anticipates a net loss attributable to shareholders of approximately HKD 59 million for the six months ending September 30, 2025, compared to a loss of about HKD 32.7 million for the same period in 2024 [1]. - The increase in losses is attributed to share-based payment expenses of approximately HKD 17.6 million and a net loss of about HKD 4.7 million from the sale of subsidiaries [1]. - After excluding the impact of share-based payments and subsidiary sales, the adjusted loss for the interim period is expected to be around HKD 36.7 million, a slight increase of approximately HKD 4 million compared to the previous year's adjusted loss of HKD 32.7 million [1]. Company Background - 港仔机器人集团控股有限公司 was established in Bermuda and listed in 1996, primarily engaged in international air and sea freight forwarding, logistics services, and trading of securities and commodities [1]. - The company has been expanding its financial services, including financing leasing in China since July 2015 and plans to develop its lending business in Hong Kong [1]. Stock Performance - The company has reported continuous losses since 2018, accumulating a total loss of HKD 740 million over seven years [2]. - The stock price has been on a downward trend since its second year of listing, reaching a record low of HKD 0.073 per share in September last year [2]. - Despite a brief surge in stock price to HKD 1.92 per share on June 9 this year, the upward momentum could not be sustained [2]. - As of November 20, the stock price has declined by 4.90%, trading at HKD 0.97 per share [3].

董事会认为除税后净利润的减少主要乃由于为支持集团不断扩展的业务而聘请更多员工。 智通财经APP讯，ECI TECH(08013)发布公告，预计本集团于报告年度(截至2025年8月31日止年度)的除 税后净利润较截至2024年8月31日止年度减少不少于65%。 ...

Core Viewpoint - Changli Holdings (08098) anticipates a significant decrease in shareholder profit for the six months ending September 30, 2025, with an expected profit of approximately HKD 7.6 million, compared to an estimated profit of HKD 24.8 million for the six months ending September 30, 2024 [1] Financial Performance - The company expects a reduction in profit primarily due to anticipated impairments in receivables, with expected losses of approximately HKD 2.6 million from loans and HKD 4.2 million from trade receivables [1]

Core Viewpoint - The company expects a significant decrease in profit attributable to shareholders for the six months ending September 30, 2025, projecting a profit of no less than approximately 300,000 HKD, compared to 3,040,000 HKD in the same period last year [1] Summary by Relevant Categories Financial Performance - The anticipated profit for the upcoming period is approximately 300,000 HKD, a decline from the previous year's profit of 3,040,000 HKD [1] Cost Factors - The board attributes the profit decline primarily to increased operating costs due to service costs, which have led to a reduction in gross profit [1] - Additionally, there has been an increase in administrative expenses related to employee costs [1]

Core Viewpoint - Novo Nordisk has announced a significant layoff plan and lowered its full-year operating profit forecast shortly after the new CEO took office, indicating a strategic shift in response to market changes, particularly in the weight loss drug sector [2][9]. Group 1: Layoff Plan - Novo Nordisk plans to cut approximately 9,000 jobs globally from a total of 78,400 positions, with around 5,000 layoffs expected in Denmark [5]. - The layoffs will affect various departments, including logistics support and headquarters functions, with communication to impacted employees expected in the coming months [7]. - The company anticipates annual savings of 8 billion Danish kroner (approximately $1.26 billion) by the end of 2026, with these funds redirected towards growth opportunities in diabetes and obesity treatment [7]. Group 2: Financial Impact - The restructuring plan is expected to incur a one-time cost of 8 billion Danish kroner, including impairment charges, with 9 billion Danish kroner in restructuring costs anticipated in Q3 2025 and savings of about 1 billion Danish kroner in Q4 [7]. - Novo Nordisk has revised its operating profit growth forecast for 2025 to a range of 4% to 10%, down from a previous estimate of 10% to 16%, marking the third downward adjustment for the year [9]. - The company has not adjusted its revenue growth forecast, which remains at 8% to 14% for the year [10]. Group 3: Market Context - The company is facing a critical moment as the market share of its weight loss drug Wegovy is declining, and sales growth is slowing, particularly in the U.S. market [9]. - Novo Nordisk's market capitalization has dropped significantly, from a peak of $650 billion to approximately $185 billion, with a loss of $70 billion in market value in July alone [9].

Group 1 - The company, 易和国际控股, expects a significant decrease in net profit for the six months ending June 30, 2025, projecting a profit of between RMB 7 million to RMB 10 million compared to approximately RMB 18.8 million for the same period ending June 30, 2024 [1] - The reduction in profit is primarily attributed to a decrease in revenue, which is linked to weakened market demand for the company's disposable plastic food containers after a notable increase in sales over the past two years [1]

Core Viewpoint - The company expects a significant decrease in profit for the six months ending June 30, 2025, compared to the same period in 2024, primarily due to the absence of gains from the sale of subsidiaries and a reduction in profits from associated companies [1] Financial Performance - The profit for the six months ending June 30, 2024, was approximately HKD 107 million [1] - The expected profit for the six months ending June 30, 2025, is projected to be around HKD 44.866 million [1] - The decrease in profit is mainly attributed to the absence of approximately HKD 49.028 million in gains from the sale of subsidiaries for the 2025 period [1] - Additionally, the share of profits from associated companies is expected to decrease by approximately HKD 21.019 million for the same period [1]

Core Viewpoint - The company expects a significant decrease in profit for the six months ending June 30, 2025, compared to the same period in 2024, primarily due to the absence of gains from the sale of subsidiaries and a reduction in profits from associated companies [1] Financial Performance - For the six months ending June 30, 2024, the company reported a profit of approximately HKD 107 million [1] - The projected profit for the six months ending June 30, 2025, is expected to drop to about HKD 44.87 million [1] - The decrease in profit is mainly attributed to the absence of approximately HKD 49.03 million in gains from the sale of subsidiaries, which were recorded in the previous period [1] - Additionally, the share of profits from associated companies is expected to decline by approximately HKD 21.02 million for the upcoming period [1]